MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

MiMedx Group, Inc.NASDAQ: MDXG

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items growth accelerates

Q1 FY2026 other non-cash items of $1.91M rose 57.4% year over year, ahead of the -248.7% change in trailing-twelve-month other non-cash items. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Other non-cash items amounted to 2.0% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +57.4% holds above the trailing-twelve-month pace of -248.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.91M+116.9% QoQ
Last fiscal yearDec 2025
$8.42M+244.8% YoY
LTMMar 2026
-$5.99M-248.7% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.4%——
1 year+244.8%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
8.42M USD
Year-over-year change
+244.8%
4-year CAGR
-5.0%

Other Non-Cash Items vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 other non-cash items of $5.99M is the 6th largest of the 8 companies compared; the peer median is $18.53M.
  • Its year-over-year change of -248.7% is the 7th highest of 8, against a peer median of +141.4%.
  • Other non-cash items amounts to 1.5% of revenue for MDXG, versus a peer median of 7.5%.
MDXG Competitors Peer median
Other Non-Cash Items for MDXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$47.4M +606.5%+135.3%320.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35.97M -21.0%+13.5%7.0%
CELUCelularity Inc.LTM Dec 2025$27.2M +141.4%—102.4%
BSEMBioStem Technologies, Inc.LTM Jun 2026$18.53M +3594.4%+268.4%—
SMTISanara MedTech Inc.LTM Mar 2026$8.5M +294.7%+47.8%7.9%
MDXGMiMedx Group, Inc.LTM Mar 2026$5.99M -248.7%+11.8%1.5%
RCELAVITA Medical, Inc.LTM Mar 2026$3.34M +84.6%+25.7%4.6%
MDWDMediWound Ltd.LTM Mar 2026$915.33K -755.7%—6.3%
Peer median (excluding MDXG) $18.53M+141.4%+47.8%7.5%

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.3M)(19.95M)67.44M42M48.58M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
Deferred Income Tax00(37.8M)12.47M8.71M
Stock-Based Compensation14.16M11.33M16.96M16.93M16.4M
Change in Working Capital(19.35M)(8.01M)(18.42M)(5.43M)(22.98M)
Accounts Receivables(10.62M)(5.94M)(12.24M)(2.55M)(26.39M)
Inventory(1.41M)(1.79M)(7.84M)(2.36M)(1.53M)
Accounts Payables(159K)839K783K(1.41M)2.12M
Other Working Capital(7.17M)(1.12M)876K885K2.83M
Other Non-Cash Items10.33M6.03M(4.83M)(5.81M)8.42M
Operating Cash Flow(1.98M)(17.89M)26.78M66.2M74M
Capital Expenditures(3.22M)(1.51M)(1.99M)(1.68M)(1.03M)
Acquisitions (Net)024K0(7.86M)(3.76M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(177K)(1.15M)(168K)(38K)0
Investing Cash Flow(3.4M)(2.66M)(2.16M)(9.58M)(6.89M)
Debt Repayment(38K)(41K)(52K)(31.72M)(1M)
Common Stock Issued0651K997K00
Common Stock Repurchased(4.75M)(1.19M)(9.52M)(2.64M)(3.12M)
Dividends Paid00000
Other Financing Activities1.44M(41K)9.46M159K(1.29M)
Financing Cash Flow(3.35M)(580K)(8.57M)(34.2M)(5.41M)
Effect of Forex Changes00000
Net Change in Cash(8.73M)(21.13M)16.05M22.42M61.71M
Free Cash Flow(5.2M)(19.41M)24.79M64.52M72.97M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.